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Abstract
The C-type lectin DC-SIGN binds to oligosaccharides on the human and simian immunodeficiency virus (HIV, SIV) envelope glycoproteins and
promotes infection of susceptible cells. Here, we show that DC-SIGN recognizes glycans involved in SIV sensitivity to neutralizing antibodies and
that binding to DC-SIGN confers neutralization resistance to an otherwise sensitive SIV variant. Moreover, we provide evidence that mannose-
binding lectin (MBL) can interfere with HIV-1 neutralization by the carbohydrate-specific antibody 2G12.
© 2007 Elsevier Inc. All rights reserved.Keywords: SIV; DC-SIGN; MBL; Neutralization; Attachment; AntibodyIntroduction
DC-SIGN (CD209) is a calcium-dependent (C-type) lectin
that was identified as a human immunodeficiency virus (HIV)
envelope protein (Env) binding factor in placental tissue (Curtis
et al., 1992). Subsequently, it was shown that DC-SIGN is
expressed at high levels on dendritic cells (DCs) and proposed
that DC-SIGN might be responsible for much of the well-docu-
mented capability of DCs to capture and transfer the virus to
adjacent T-cells (trans-infection) (Geijtenbeek et al., 2000).
Since the latter process might be important for dissemination of
sexually transmitted HIV (Wu and KewalRamani, 2006), a role
for DC-SIGN as an HIV transmission promoting factor has been
suggested (Geijtenbeek et al., 2000, 2001b). While several⁎ Corresponding author. Hannover Medical School, Institute of Virology, OE
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doi:10.1016/j.virol.2007.07.004reports support important features of this model (Arrighi et al.,
2004a, 2004b; Gurney et al., 2005; Hu et al., 2004; Liu et al.,
2004, 2006; Martin et al., 2004), it has also been demonstrated
that the majority of HIV taken up by DCs is degraded and
processed for MHC presentation (Moris et al., 2004, 2006) and
that DC-SIGN-dependent transmission is a short lived process
(Burleigh et al., 2006; Nobile et al., 2005; Turville et al., 2004).
Nevertheless, recent reports of DC-SIGN-mediated HIV inter-
actions with platelets (Boukour et al., 2006; Chaipan et al., 2006)
and activated B-cells (He et al., 2006; Rappocciolo et al., 2006)
reinforce the notion that certain motile cells might capture HIV
via DC-SIGN andmight thereby promote viral spread in infected
individuals.
Experimental infection of macaques with simian immuno-
deficiency virus (SIV) is one of the best models for HIV/AIDS in
humans. Macaque and human DC-SIGN transmit HIV and SIV
with similar efficiency (Baribaud et al., 2001; Geijtenbeek et al.,
2001a; Ploquin et al., 2004;Wu et al., 2002a). However, the DC-
SIGN-related proteins DC-SIGNR/L-SIGN/CD209L (humans)
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(macaques) (Bashirova et al., 2003) differ in their ability to
interact with these viruses, with only DC-SIGNR being com-
petent for HIV and SIV transmission (Bashirova et al., 2001,
2003; Pöhlmann et al., 2001b). DC-SIGN recognizes high-
mannose carbohydrates on the HIV and SIV Env proteins
(Appelmelk et al., 2003; Guo et al., 2004; Hong et al., 2002; Lin
et al., 2003).Mutagenic analysis revealed that several glycans on
HIV Env are involved in DC-SIGN binding (Hong et al., 2002)
and that the DC-SIGN binding site partially overlaps with the
epitope of the neutralizing antibody 2G12 (Binley et al., 2006;
Hong et al., 2007). Glycans on the HIVand SIV Env proteins are
required for protection from neutralizing antibodies (Pikora et
al., 2006). Thus, the parental SIVmac239 virus is highly resistant
to antibody-mediated neutralization, while SIVmac239 variants
with mutations in certain N-linked glycosylation sites are
neutralization sensitive (Reitter et al., 1998). However, it is
currently unclear whether glycans involved in SIV neutralization
sensitivity are also required for DC-SIGN binding. Here, we
investigated if glycosylation sites known to impact SIV
neutralization sensitivity also modulate DC-SIGN usage and
we asked if DC-SIGN binding can confer neutralization
resistance to an otherwise neutralization sensitive SIV variant
with altered glycosylation signals. Moreover, we analyzed if
mannose-binding lectin (MBL), a soluble lectin in human serum,Fig. 1. CD209L2 does not transmit HIV and SIV but enhances cis-infection driven
transfer. B-THP cell lines expressing the indicated lectins were incubated with S
SIVmac239 variant as negative control (all produced in 293T cells). For this, 50,000
CEMx174 R5 cells) of SIVmac239 and 316 or with a maximum volume of V3-d
permissive CEMx174 R5 cells which express luciferase under control of the viral LTR
were determined. The results of a representative experiment performed in quadrupl
indicate standard deviation (SD), statistical significance was calculated using t-test
HIV-1. Lectin-dependent transmission of HIV-1 NL4-3 was assessed as described in
experiment performed in quadruplicates is shown. Similar results were obtained in
calculated using t-test for independent samples. Hu, human; rh, rhesus macaque (C) C
The indicated lectin expressing cells were seeded in 96-well plates at a concentration
concentration) and infected with SIV reporter virus bearing EBOV-GP. The luciferase
representative experiment performed in quadruplicates are presented and were confir
macaque.modulates HIV-1 neutralization by the carbohydrate-specific
monoclonal antibody 2G12 (Buchacher et al., 1994; Sanders
et al., 2002).
Results
DC-SIGN and CD209L2 augment Ebola virus
glycoprotein-driven cis-infection with similar efficiencies
In order to address the contribution of specific glycans in SIV
Env to SIV interactions with DC-SIGN, we first attempted to
confirm previous reports indicating that macaque DC-SIGN but
not the related lectin CD209L2 can transmit SIV (Bashirova et
al., 2003). Transmission of SIV by human and macaque DC-
SIGN and macaque CD209L2 was assessed employing B-THP
cell lines exogenously expressing these lectins as transmitters, as
described previously (Baribaud et al., 2002; Bashirova et al.,
2003). Lectin expression on these cell lines was comparable, as
judged by FACS analysis (data not shown). In agreement with
published studies (Baribaud et al., 2001; Bashirova et al., 2003;
Geijtenbeek et al., 2001a; Ploquin et al., 2004; Wu et al., 2002a),
we found that human and macaque DC-SIGN transmitted
SIVmac239 and the macrophage tropic SIVmac239 variant 316
(Mori et al., 1993) with high efficiency, while transmission by
CD209L2 was relatively inefficient (Figs. 1A and 2A). Similarby Ebola virus glycoprotein. (A) DC-SIGN but not CD209L2 augments SIV
IVmac239, the macrophage-tropic SIVmac239 variant 316 or a V3-deleted
cells were mixed with 1,500 tissue culture infectious doses (as determined on
eleted virus stock. Subsequently, the cells were washed and cocultivated with
. Three days after the start of the cocultures luciferase activities in cellular lysates
icates are shown and were confirmed in three separate experiments. Error bars
for independent samples. Rh, rhesus macaque (B) CD209L2 does not transmit
panel A; however, input virus was normalized for p24-content. A representative
two separate experiments. Error bars indicate SD, statistical significance was
D209L2 augments infection driven by the Ebola virus glycoprotein (EBOV-GP).
of 30,000 cells per well, incubated with mAb 526 or control IgG (10 μg/ml final
activities in the cultures were determined 3 days post-infection. The results of a
med in two separate experiments. Error bars indicate SD. Hu, human; rh, rhesus
Fig. 2. DC-SIGN-mediated transmission of SIV variants with mutations in N-linked glycosylation signals. (A) Transmission of SIV glycosylation site variants by
DC-SIGN. The transmission assay was carried out as described in the legend to Fig. 1A, employing infectivity normalized viruses. B-THP cell lines engineered to
express human DC-SIGN (huDC-SIGN), rhesus macaque DC-SIGN (rhDC-SIGN) or parental B-THP cells were used as transmitters. In parallel, direct infection of
CEMx174 R5 cells in the absence of transmitters was assessed and results are shown in panel B. Representative experiments performed in quadruplicates are
presented in panels A and B. The results were confirmed in five separate experiments. Error bars indicate SD, statistical significance was calculated using t-test for
independent samples.
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macaque DC-SIGN and CD209L2 strongly augmented cis-
infection (direct infection of the lectin expressing cells) driven
by SIV-derived pseudotypes bearing the glycoprotein of Ebola
virus (EBOV), a well-documented DC-SIGN ligand (Alvarez et
al., 2002; Simmons et al., 2003), and antibody inhibition
analysis confirmed that enhancement of infection was lectin-
dependent (the monoclonal antibody (mAb) 526 recognizes DC-
SIGN and CD209L2; Baribaud et al., 2002; Bashirova et al.,
2003; Wu et al., 2002b) (Fig. 1C). Thus, CD209L2 might not
impact SIV spread in macaques but might serve as a potent
attachment factor in the context of EBOV infection.
Glycans involved in SIV sensitivity to neutralization also
contribute to DC-SIGN binding
We next analyzed if well-characterized alterations of
SIVmac239 Env glycosylation sites (Reitter and Desrosiers,
1998), which confer neutralization sensitivity (Reitter et al.,
1998), also impact DC-SIGN-dependent SIV transfer to
susceptible cells. Thus, variant M5 harbors changes in N-linked
glycosylation signals 5, 6, 8, 12 and 13 while combinations of
the glycosylation signals 4, 5 and 6 were inactivated in variants
g4,5; g4,6 and g5,6; and all viral variants are known to be
susceptible to neutralization (Johnson et al., 2003; Reitter et al.,
1998). Analysis of DC-SIGN-mediated transmission of TCID50-
normalized viruses revealed that the variants g4,5; g4,6 and g5,6
interacted with DC-SIGN with similar efficiency as the wt virus,
while transfer of M5 was severely reduced (Fig. 2A). Direct
infection of target cells in the absence of lectin expressing cells
confirmed comparable infectivity of all viruses analyzed except
for a V3-loop deleted control virus (Fig. 2B), underlining that the
diminished DC-SIGN-driven transfer of the M5 virus was not
due to reduced infectivity for target cells. Therefore, N-linked
glycosylation signals 5, 6, 8, 12 and 13 seem to be involved inboth, protection against neutralizing antibodies and engagement
of DC-SIGN.
Binding of SIV to DC-SIGN confers resistance to
antibody-mediated neutralization
We then sought to determine if binding to DC-SIGN can
protect SIV from attack by neutralizing antibodies. The g5,6
variant was chosen for these experiments since this virus is
neutralization sensitive (Reitter et al., 1998) and engages DC-
SIGN efficiently (Fig. 2A). Investigating a potential link
between DC-SIGN binding and neutralization sensitivity
required establishment of a cellular system in which binding
to DC-SIGN readily occurs but does not augment viral
infectivity; otherwise, it would be impossible to discriminate
between DC-SIGN-dependent enhancement of infectious entry
and DC-SIGN-mediated protection against neutralizing anti-
bodies. In agreement with our previous unpublished observa-
tions, DC-SIGN-expressing 293 T-REx cells fulfilled this
requirement, provided that no wash step was included in the
transmission assay. Thus, virtually identical infection of
CEMx174 R5 target cells by the g5,6 variant was observed
independent of the presence of DC-SIGN T-REx cells, parental
T-REx control cells or PBS in the cocultures (93.34±8.16 and
84.94±8.76% infectious entry in the presence of T-REx DC-
SIGN and T-REx control cells, respectively, with entry in PBS-
treated target cells being set as 100%. Results represent the
average of six independent experiments±standard error of the
mean). This system was then employed for analysis of g5,6
neutralization. Coculture of T-REx control cells with CEMx174
R5 targets slightly increased neutralization resistance, particu-
larly when low doses of antiserum were added, and this effect
was further augmented by coculture of targets with DC-SIGN
expressing T-REx cells (Figs. 3A and B). Inhibition analysis
with mAb 526 confirmed that the enhanced neutralization
Fig. 3. Binding of SIV to DC-SIGN can protect from antibody-mediated neutralization. (A) Protection of SIV from neutralization by membrane-bound human DC-
SIGN. Infectivity normalized SIVmac239 g5,6 virus was incubated with T-REx DC-SIGN cells (Pöhlmann et al., 2001a), in the presence or absence of mAb 526, or
incubated with parental T-REx cells or PBS for 30 min in a total volume of 100 μl per well (the assay was carried out in 96-well plates). Subsequently, 50 μl of the
indicated dilutions of neutralizing serum (obtained from a g5,6-infected macaque; Reitter et al., 1998) was added. After a 30-min incubation period, 50 μl of fresh
medium containing CEMx174 R5 target cells was added to the cultures without removing free virus. Three days after the start of the cocultures, luciferase activities in
cellular lysates were determined. The results of a representative experiment are shown and were confirmed in two to six separate experiments. Error bars indicate SD.
(B) Same experimental setup as in panel A; however, the average ± SEM of six independent experiments is shown. Statistical significance was calculated using t-test
for independent samples. (C) Protection of SIV from neutralization by soluble, recombinant human DC-SIGN. Infectivity normalized g5,6 virus was incubated for
30 min with the indicated final concentrations of soluble DC-SIGN, previously expressed in Escherichia coli and purified on mannose–sepharose (Mitchell et al.,
2001), in a total volume of 100 μl. Subsequently, 50 μl of the indicated dilutions of neutralizing serum from a g5,6-infected macaque was added. As a control the g5,6
variant was first incubated with neutralizing antiserum and then the highest concentration of soluble DC-SIGN was added. After 30 min, 50 μl of fresh medium
containing CEMx174 R5 target cells was added to the cultures. Luciferase activities in cellular lysates were measured 3 days after addition of target cells. The results of
a representative experiment performed in quadruplicates are shown. Similar results were obtained in three separate experiments. Error bars indicate SD. Statistical
significance was calculated using t-test for dependent samples.
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Thus, cell-bound SIV is somewhat less sensitive to neutra-
lization than free virus and DC-SIGN expression increases
protection.
The moderate protective effect against antibody-mediated
neutralization of SIV observed with kidney-derived 293 cell
lines (Figs. 3A and B) might not appropriately reflect the in
vivo situation since in infected macaques DC-SIGN-expressing
cells are arranged in tightly packed, three-dimensional arrays in
lymphoid and mucosal tissues and might secrete soluble DC-
SIGN in the supernatant (Furmonaviciene et al., 2007; Liu et
al., 2005; Mummidi et al., 2001). Thus, a significantly higher
number of Env trimers on the virion surface might be bound to
DC-SIGN in vivo as compared to our two-dimensional cellculture system. In order to investigate whether increasing DC-
SIGN copy numbers and bypassing spatial constraints to DC-
SIGN binding can confer neutralization resistance to the g5,6
variant, we pre-incubated the virus with rising concentrations of
soluble recombinant tetrameric DC-SIGN (Mitchell et al.,
2001) before adding neutralizing antiserum and target cells
(Fig. 3C). In this experimental set-up DC-SIGN protected SIV
g5,6 efficiently and in a dose-dependent manner from
neutralization. Importantly, neutralization resistance was not
observed when soluble DC-SIGN was added subsequent to the
antiserum (Fig. 3C), suggesting that protection from neutraliza-
tion was specific and most likely due to DC-SIGN tetramers
shielding epitopes in SIV Env from recognition by neutralizing
antibodies.
Fig. 4. MBL reduces 2G12-mediated neutralization of HIV-1. A HIV-1 NL4-3
reporter virus was incubated for 30 min with the indicated concentrations of
recombinant MBL. Subsequently, the neutralizing antibody 2G12 was added at
the indicated concentrations and the samples were incubated for 30 min before
addition of CEMx174 R5 target cells. After cultivation of cells for 3 days, the
luciferase activities in cellular lysates were determined. Enzyme activities
measured in the absence of 2G12 were set as 100% and the average of three
independent experiments performed in quadruplicates is shown. Error bars
indicate SEM.
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carbohydrate-specific antibody 2G12
In order to further explore the relevance of lectin engagement
for lentiviral spread in the face of neutralizing antibodies, we
asked if lectins in human serum can affect neutralization
sensitivity of HIV-1. To this end, we investigated if soluble
MBL, a lectin present in concentrations of up to 10 μg/ml in
human serum, modulates recognition of HIV-1 by the carbohy-
drate-specific, broadly neutralizing antibody 2G12. Treatment
of HIV-1 with MBL alone caused a moderate increase in viral
infectivity (6.30±1.29-fold at the maximal MBL concentration,
average±standard error of the mean (SEM) of three independent
experiments and data not shown). Exposure of virions to
recombinant MBL prior to antibody addition provided appreci-
able protection against 2G12-mediated neutralization (Fig. 4),
with at least the difference in HIV-1 infectivity in the presence of
1 μg/ml 2G12 and either 0 or 10 μg/ml MBL being statistically
significant (p=0.03). Thus, our results are generally compatible
with the idea thatMBL andmaybe other lectins present in human
serum might interfere with HIV-1 recognition by carbohydrate-
specific agents.
Discussion
DC-SIGN and DC-SIGNR are calcium-dependent (C-type)
lectins that can augment HIV and SIV infectivity when
expressed exogenously on cell lines. Endogenous DC-SIGN
expression on DCs (Geijtenbeek et al., 2000), platelets
(Boukour et al., 2006; Chaipan et al., 2006) and B-cells (He
et al., 2006; Rappocciolo et al., 2006) has also been shown to
enhance infection by primate lentiviruses and it has been
proposed that DC-SIGN on these cell types might promote viraldissemination in and between hosts. However, the role of DC-
SIGN in DC-mediated transfer of HIV and SIV is under
discussion and an important contribution of other factors has
been established (Baribaud et al., 2002; Boggiano et al., 2006;
Gummuluru et al., 2003; Turville et al., 2002; Wu et al., 2002a).
Moreover, it should be noted that DC-SIGN can augment cis-
and trans-infection (Burleigh et al., 2006; Lee et al., 2001;
Nobile et al., 2005; Turville et al., 2004) and it can not be
excluded that a minor part of the transmission activity of the B-
THP cell lines examined here was due to progeny virus released
from infected transmitters. The expression of DC-SIGN and
DC-SIGNR differs among humans and non-human primates.
Humans express DC-SIGN and DC-SIGNR, while the latter is
absent in monkeys which instead encode a related protein
termed CD209L2 (Bashirova et al., 2003). CD209L2, like DC-
SIGNR, has been detected in liver and lymph nodes (Bashirova
et al., 2003). However, in contrast to DC-SIGNR, CD209L2
was found to be unable to efficiently augment trans-infection of
HIV-1 and SIV (Bashirova et al., 2003). We confirmed this
observation but also noted that CD209L2 was able to robustly
augment EBOV-driven cis-infection and might therefore
modulate EBOV spread in infected macaques.
It has long been proposed that oligosaccharides on the
surface of HIV and SIV Env protect these proteins from
recognition by neutralizing antibodies. Strong experimental
evidence for such an effect was reported by Reitter and
colleagues (1998) who demonstrated that inactivation of highly
conserved glycosylation signals in SIVmac239 Env by side-
specific mutagenesis yields viral variants which, in contrast to
the wt virus, are highly neutralization sensitive. Sera from
macaques experimentally infected with some of these variants
exhibited augmented reactivity against peptides spanning the
altered glycosylation signals and were capable of neutralizing
the wt virus (Reitter et al., 1998), indicating that certain glycans
in SIV Env prevent the generation of an effective neutralizing
antibody response. Our results show that some of these
oligosaccharides are also involved in binding to DC-SIGN.
Thus, removal of glycosylation signals 5, 6, 8, 12 and 13 in
variant M5, which rendered the mutant virus neutralization
sensitive (Reitter et al., 1998), strongly reduced DC-SIGN
engagement. In contrast, mutation of glycosylation signals 5
and 6 together or mutation of a single site in combination with
alteration of glycosylation site 4 did not appreciably diminish
interactions with DC-SIGN. These results suggest that glyco-
sylation signals 4, 5 and 6, which are used in the wt virus
(Reitter and Desrosiers, 1998), might not be involved in DC-
SIGN binding. Alternatively, the glycans attached to signals 5
and 6 might be recognized by DC-SIGN and defects in these
glycosylation sites might be compensated by carbohydrates
attached at positions 8, 12 and 13. In fact, mutation of
glycosylation site 5 and 6 in the M5 variant might affect
processing of glycans 8, 12 and 13, which, under these
conditions, might be exclusively of the high-mannose type (the
type of carbohydrate bound by DC-SIGN). In any event, the
diminished but not abrogated DC-SIGN interactions with the
M5 virus clearly suggest that several glycans in SIV Env might
be required for DC-SIGN binding and most or all of these
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neutralizing antibodies (Reitter et al., 1998).
Since an overlapping set of glycans was involved in DC-
SIGN engagement and in SIV sensitivity to neutralization, we
analyzed whether DC-SIGN binding protects SIV from anti-
body-mediated neutralization. Attachment of virus to DC-SIGN
expressing cells indeed exerted a modest but readily detectable
protective effect. More impressively, pre-incubation of virions
with soluble, tetrameric DC-SIGN resulted in highly efficient,
dose-dependent protection from neutralizing antibodies. Why
was soluble DC-SIGN more efficient in protecting SIV from
antibody recognition than membrane-bound protein? First,
roughly 1,000 to 10,000 more DC-SIGN tetramers were
available for SIV binding in the assays carried out with soluble
relative to membrane-bound DC-SIGN. Second, the spatial
constraints to ligand recognition imposed by membrane
insertion of DC-SIGN did not afflict SIV binding to soluble
DC-SIGN. Thus, usage of soluble relative to membrane-
associated DC-SIGN most likely allowed DC-SIGN binding
to a higher percentage of virion incorporated Env trimers and
thereby provided more efficient protection against antibodies.
Since soluble DC-SIGN, in agreement with previous data
(Kwon et al., 2002), did not alter SIV infectivity and had no
protective effect when added subsequently to the neutralizing
antiserum, we believe that protection was most likely due to
steric hindrance, with DC-SIGN covering epitopes recognized
by neutralizing antibodies.
Whether DC-SIGN can indeed shield neutralization sensitive
HIV and SIV variants from antibody recognition in the infected
host needs to be elucidated. However, three-dimensional arrays
of DC-SIGN-positive cells in lymphoid tissues or in the
anogenital mucosa may simultaneously bind to more Env
trimers on the virion surface than cell lines commonly used to
study DC-SIGN function. Moreover, several studies reported
that alternative splicing of endogenous DC-SIGN and DC-
SIGNR readily occurs in primary cells and can result in
production of secreted lectins lacking the transmembrane
domain (Liu et al., 2005; Mummidi et al., 2001). Finally, recent
data indicate the presence of a protease-sensitive region within
DC-SIGN, at an N-terminal sequence close to the outer bilayer
of the plasma membrane, that is highly susceptible to cleavage
by a number of eukaryotic enzymes (Feinberg et al., 2005;
Furmonaviciene et al., 2007). Thus, certain tissues and
compartments of the infected host might contain sufficient
soluble and membrane-bound DC-SIGN to shield a fraction of
the local viruses against neutralizing antibodies. In addition, a
very recent study by van Montfort and colleagues (2007)
suggests that DC-SIGN might protect HIV-1 from neutraliza-
tion by antibodies even after antibody binding. This group
demonstrates that DC-SIGN on cell lines and monocyte-derived
dendritic cells mediates efficient capture of HIV-1 bound by
broadly neutralizing antibodies and that captured virions are
highly infectious for co-cultured T-cells. It is proposed that
antibody-bound virus is internalized into endosomal compart-
ments where low pH dissociates the virus–antibody complexes,
followed by recycling of infectious virus to the cell surface and
transfer to target cells (van Montfort et al., 2007). Therefore,DC-SIGN might provide HIV and SIV with an efficient two-
step protection against neutralizing antibodies, shielding of
epitopes from antibody recognition and release of bound
antibodies upon intracellular uptake of virions, which can
subsequently be transmitted to T-cells.
A potential impact of lectins on the neutralization sensitivity
of lentiviruses is further highlighted by our observation that
MBL can interfere with HIV-1 recognition by the carbohydrate-
specific antibody 2G12. MBL is present in human serum in
concentrations ranging from 20 to 10,000 ng/ml and readily
opsonizes HIV-1 (Dommett et al., 2006). However, MBL
binding does not induce substantial HIV-1 neutralization (Ying
et al., 2004). In contrast to previous studies (Dommett et al.,
2006), we even observed slight augmentation of infectivity
upon HIV-1 exposure to MBL. Differences in the cell types
used for virus production (kidney-derived 293T cells versus T-
cell lines) might account for this discrepancy. Pre-incubation
with MBLmoderately protected the CXCR4-tropic HIV-1 NL4-
3 against neutralization by 2G12, a broadly neutralizing
antibody, which, like MBL and DC-SIGN, recognizes man-
nose-rich N-glycans (Sanders et al., 2002). It is therefore
conceivable that the level of MBL in patients might impact the
efficiency of 2G12 treatment, which can reduce virus replica-
tion in infected patients (Trkola et al., 2005).
In summary, we provide evidence that engagement of DC-
SIGN by otherwise neutralization sensitive SIV variants can
confer efficient protection against neutralization. Moreover, our
data suggest that MBL can modulate HIV-1 recognition by the
broadly neutralizing antibody 2G12. These results and a recent
report (van Montfort et al., 2007) demonstrate that attachment to
DC-SIGN, MBL and possibly other lectins might allow some
degree of viral spread despite the presence of neutralizing
antibodies, which has implications for the design of vaccines
and antibodies for therapy and prevention.
Materials and methods
Plasmid construction and cell culture
The envelope sequences of SIVmac239 variants 316, M5,
g4,5; g4,6 and g5,6 (Reitter and Desrosiers, 1998; Reitter et al.,
1998) were SphI and NheI inserted into the SIVmac239 genome
contained in a pBR322-derived plasmid. The SIVmac239 ΔV3
variant has been described previously (Pöhlmann et al., 1999).
Generation of 293 T-REx and B-THP cell lines expressing DC-
SIGN has been described previously (Geijtenbeek et al., 2000;
Pöhlmann et al., 2001a; Wu et al., 2004). The CEMx174 R5
cells express exogenous CCR5 and contain expression cassettes
for EGFP and luciferase under control of the viral LTR (Hsu et
al., 2003). T-REx cells and 293T cells were maintained in
Dulbecco's modified Eagle's medium (DMEM; PAA) supple-
mented with 10% FCS, penicillin and streptomycin. In addition,
the culture medium for parental T-REx cells was supplemented
with 2.5 μg/ml blasticidin (Invitrogen), while medium for T-
REx DC-SIGN cells contained 2.5 μg/ml blasticidin and 50 μg/
ml zeocin (Invitrogen). Culture medium for parental and lectin
expressing B-THP cell lines and CEMx174 M7 R5 cells was
328 A. Marzi et al. / Virology 368 (2007) 322–330RPMI (PAA), supplemented with 10% FCS, penicillin and
streptomycin.
Virus production and normalization
SIVmac239 viruses were produced by transfection of 293T
cells with plasmids encoding proviral DNA. Two days after
transfection the culture supernatants were harvested, passed
through 0.4 μm pore-size filters, aliquoted and stored at −80 °C.
For subsequent infection experiments, the TCID50 of each SIV
stock was assessed using serial virus dilutions for infection of
CEMx174 M7 R5 cells. For each dilution 6 parallel wells of a
96-well plate were infected. After 3 days the infected wells were
counted and the results were used to determine the TCID50
employing a previously described method. Lentiviral pseudo-
types bearing ZEBOV-GP and encoding luciferase were
generated as described (Marzi et al., 2006). Pseudotypes were
normalized for luciferase production upon infection of 293T
cells using a commercially available kit as recommended by
the manufacturer (Promega, WI, USA). Replication-competent
HIV-1 NL4-3 luciferase encoding reporter virus (NL4-3luc)
was produced as described (Pöhlmann et al., 2001a) and
stocks were normalized for p24-antigen content employing a
commercially available antigen capture ELISA (Murex;
Abbott Diagnostics).
Infection, transmission and neutralization experiments
Transmission of SIV and HIV-1 was analyzed as described
previously (Baribaud et al., 2002; Pöhlmann et al., 2001a). In
brief, 5×104 B-THP cells were incubated with equal volumes
of viral supernatants containing 1,500 TCID50 of each
SIVmac239 variant or 5 ng p24-antigen of HIV-1 NL4-3 luc.
Thereafter, cells were washed and cocultured with 3×104
CEMx174 M7 R5 target cells. Three days after the start of the
cocultivation cells were lysed and luciferase activities in
cellular lysates determined. Lectin-mediated enhancement of
ZEBOV-GP-driven infection was analyzed as follows. The
indicated B-THP cell lines were seeded into 96-well plates at a
density of 3×104 per well, pre-incubated with either PBS or
the DC-SIGN/R-specific mAb 526 (R&D Systems) at a final
concentration of 10 μg/ml for 30 min at 37 °C and then
infected with infectivity-normalized ZEBOV-GP pseudotypes.
Luciferase activities in cell lysates were determined 3 days
after infection. For neutralization experiments with T-REx cell
lines, the cells were seeded into 96-well plates at a density of
3×104 per well and lectin expression induced overnight with
doxycycline (dox) at a final concentration of 100 ng/ml. The
cells were then pre-incubated with PBS or mAb 526 (10 μg/ml
final concentration) for 30 min followed by incubation with
1,500 TCID50 per well of the SIV variants. After incubation for
30 min at 37 °C, the serum of a SIVmac239 g5,6-infected
macaque (Reitter et al., 1998) was added to the mixture at the
indicated dilutions and the cells again incubated for 30 min.
Finally, 3×104 CEMx174 M7 R5 target cells were added to
each well and 72 h later luciferase activities in cellular lysates
were determined.The setup for inhibition experiments with soluble tetrameric
DC-SIGN (sol DC-SIGN) and recombinant human MBL (R&D
Systems) was similar: 1,500 TCID50 of the SIVmac239 variant
g5,6 or 7 ng HIV-1 NL4-3luc were pre-incubated with the
indicated final concentrations of soluble DC-SIGN or MBL for
30 min at 37 °C in a 96-well plate (the generation of soluble
DC-SIGN has been previously described in detail; Mitchell et
al., 2001). Afterwards the serum of a SIVmac239 g5,6-infected
macaque or the HIV-1 neutralizing monoclonal antibody 2G12
(NIH AIDS Research and Reference Program) was added to the
mixture at the indicated dilutions/concentrations. After a second
incubation period, 3×104 CEMx174 M7 R5 cells were added to
each well and 72 h later luciferase activities in cellular lysates
were determined.
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